In Vivo Infographics
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.

In Vivo's 2022 Rising Leaders At A Glance
Top 30 Leaders: see the list of entrepreneurs and innovators highlighted in the third edition of In Vivo's Rising Leaders series.

Snapshot: March Highlights
A selection of articles you might have missed from March 2022, including exclusive interviews and an in-depth look at the targeted protein degradation field.

Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

2021 Deal-Making Snapshot
M&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.

Infographic: 2021 Top Big Pharma Deal-Makers
Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.

Snapshot: January Highlights
A selection of articles you might have missed from January 2022, including exclusive interviews and a look at the oncology microbiome pipeline.

When It Comes To Sponsor Meetings, FDA Is Getting A ‘D’
New ‘Type D’ meetings will be added as part of PDUFA VII, one of a spate of changes under the next version of the user fee program that will begin in October 2022.

Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.

Snapshot: August Highlights
A selection of articles you might have missed from August 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.

Alzheimer’s Disease: Many Failures Before One Success
For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. In Vivo's sister publication Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over the past decade to showcase exactly how difficult the Alzheimer’s space has been.

Snapshot: July Highlights
A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.